XML 30 R19.htm IDEA: XBRL DOCUMENT v3.7.0.1
Subsequent Events
 6 Months Ended
Jun. 30, 2017
Subsequent Events [Abstract]  
Subsequent Events

13.

Subsequent Events

 

In July 2017, the Company recorded revenue of $20,000 in connection with the initiation of the SER-109 Phase 3 clinical study (ECOSPOR III) in patients with multiply recurrent CDI, upon achievement of the related milestone under the License Agreement.